Halozyme Therapeutics Inc. (HALO) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
12390 EL CAMINO REAL SAN DIEGO, CA 92130 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 118,370 | 362,794 | 740,922 | 368,013 | 120,179 | 354,526 | |||
| Cash and cash equivalents | 118,370 | 234,195 | 118,719 | 147,703 | 120,179 | 57,936 | |||
| Short-term investments | 128,599 | 622,203 | 220,310 | 296,590 | |||||
| Receivables | 231,072 | 90,975 | 97,730 | 59,442 | 30,005 | ||||
| Inventory, net of allowances, customer advances and progress billings | 127,601 | 100,123 | 53,908 | 60,747 | 29,359 | 22,625 | |||
| Inventory | 127,601 | 100,123 | 53,908 | 60,747 | 29,359 | 22,625 | |||
| Prepaid expense | 36,850 | 30,156 | 8,230 | ||||||
| Contract with customer, asset, after allowance for credit loss | 1,000 | ||||||||
| Derivative instruments and hedges, assets | |||||||||
| Other undisclosed current assets | 462,603 | 45,024 | 40,482 | 28,274 | 304,300 | 12,463 | |||
| Total current assets: | 746,424 | 739,013 | 926,287 | 554,764 | 543,436 | 427,849 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 36,836 | 40,469 | 2,003 | ✕ | |||||
| Property, plant and equipment | 38,108 | 35,101 | 6,791 | 10,593 | 10,855 | 7,465 | |||
| Intangible assets, net (including goodwill) | 889,700 | 955,701 | |||||||
| Goodwill | 416,821 | 409,049 | |||||||
| Intangible assets, net (excluding goodwill) | 472,879 | 546,652 | |||||||
| Derivative instruments and hedges | |||||||||
| Restricted cash and investments | 500 | 500 | 500 | 500 | 500 | ||||
| Deferred income tax assets | 4,386 | 44,426 | 155,434 | ✕ | |||||
| Other undisclosed noncurrent assets | 17,816 | 26,301 | 13,414 | 14,067 | 11,083 | 4,434 | |||
| Total noncurrent assets: | 986,846 | 1,102,498 | 178,142 | 25,160 | 22,438 | 12,399 | |||
| TOTAL ASSETS: | 1,733,270 | 1,841,511 | 1,104,429 | 579,924 | 565,874 | 440,248 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 112,494 | 114,209 | 25,982 | 22,411 | 62,083 | 53,608 | |||
| Accounts payable | 11,816 | 17,693 | 1,541 | 1,928 | 6,434 | 4,079 | |||
| Accrued liabilities | 100,678 | 96,516 | 24,441 | 20,483 | 55,649 | 49,529 | |||
| Deferred revenue | 3,246 | 1,746 | 1,746 | ✕ | |||||
| Debt | 13,334 | 89,419 | 397,228 | 19,542 | 91,506 | ||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 4,247 | ||
| Other undisclosed current liabilities | 4,012 | ||||||||
| Total current liabilities: | 112,494 | 130,789 | 117,147 | 421,385 | 85,637 | 149,361 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 1,499,248 | 1,492,766 | 787,255 | 383,045 | |||||
| Long-term debt, excluding current maturities | 1,499,248 | 1,492,766 | 787,255 | 383,045 | |||||
| Liabilities, other than long-term debt | 37,720 | 48,158 | 3,074 | 7,492 | 5,427 | 7,126 | |||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 5,008 | ||
| Deferred revenue | 2,253 | 2,530 | 4,026 | 1,247 | ✕ | ||||
| Other liabilities | 37,720 | 30,433 | 544 | 3,466 | 4,180 | 2,118 | |||
| Business combination, contingent consideration, liability | 15,472 | ||||||||
| Total noncurrent liabilities: | 1,536,968 | 1,540,924 | 790,329 | 7,492 | 388,472 | 7,126 | |||
| Total liabilities: | 1,649,462 | 1,671,713 | 907,476 | 428,877 | 474,109 | 156,487 | |||
| Equity | |||||||||
| Equity, attributable to parent | 83,808 | 169,798 | 196,953 | 151,047 | 91,765 | 248,887 | |||
| Common stock | 127 | 135 | 138 | 135 | 137 | 145 | |||
| Additional paid in capital | 2,409 | 27,368 | 256,347 | 625,483 | 695,066 | 780,457 | |||
| Accumulated other comprehensive income (loss) | (9,278) | (922) | (620) | 22 | 240 | (277) | |||
| Retained earnings (accumulated deficit) | 90,550 | 143,217 | (58,912) | (474,593) | (603,678) | (531,438) | |||
| Total equity: | 83,808 | 169,798 | 196,953 | 151,047 | 91,765 | 248,887 | |||
| Other undisclosed liabilities and equity | 34,874 | ||||||||
| TOTAL LIABILITIES AND EQUITY: | 1,733,270 | 1,841,511 | 1,104,429 | 579,924 | 565,874 | 440,248 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 829,253 | 660,116 | 443,310 | 267,594 | 195,992 | 151,862 | ||
| Revenue, net | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 151,862 | |
| Cost of revenue (Cost of Goods and Services Sold) | (192,361) | (139,304) | (81,413) | (43,367) | (45,546) | (10,136) | ||
| Gross profit: | 636,892 | 520,812 | 361,897 | 224,227 | 150,446 | 141,726 | ||
| Operating expenses | (299,318) | (253,281) | (85,995) | (79,972) | (218,056) | (211,056) | ||
| Operating income (loss): | 337,574 | 267,531 | 275,902 | 144,255 | (67,610) | (69,330) | ||
| Nonoperating income | 16,317 | 1,046 | 1,102 | 5,425 | 6,986 | 7,577 | ||
| Other nonoperating income | 16,317 | 1,046 | 1,102 | 5,425 | 6,986 | 7,578 | ||
| Interest and debt expense | (18,762) | (19,659) | (28,486) | (20,378) | (12,028) | (18,041) | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | 335,129 | 248,918 | 248,518 | 129,302 | (72,652) | (79,794) | ||
| Other undisclosed income from continuing operations before income taxes | 13,200 | 401 | 1 | |||||
| Income (loss) from continuing operations before income taxes: | 348,329 | 248,918 | 248,518 | 129,302 | (72,251) | (79,793) | ||
| Income tax expense (benefit) | (66,735) | (46,789) | 154,192 | (217) | 11 | (537) | ||
| Income (loss) from continuing operations: | 281,594 | 202,129 | 402,710 | 129,085 | (72,240) | (80,330) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | 402,710 | 129,085 | (72,240) | (80,330) | |
| Net income (loss) available to common stockholders, diluted: | 281,594 | 202,129 | 402,710 | 129,085 | (72,240) | (80,330) | ||
Comprehensive Income ($ in thousands)
| 3/31/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 281,594 | 202,129 | 402,710 | 129,085 | (72,240) | (80,330) | ||
| Other comprehensive income (loss) | 24 | 8 | 15 | (32) | 9 | (8) | ||
| Comprehensive income (loss): | 281,618 | 202,137 | 402,725 | 129,053 | (72,231) | (80,338) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (8,380) | (310) | (657) | (186) | 508 | 181 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 273,238 | 201,827 | 402,068 | 128,867 | (71,723) | (80,157) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.